Overview

Japanese BAY88-8223 Monotherapy Phase II Study

Status:
Completed

Trial end date:
2017-05-16

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of the best standard of care plus BAY88-8223 in Japanese patients with CRPC and bone metastases after a multiple administration

Phase:

Phase 2

Details

Lead Sponsor:

Bayer

Treatments:

Radium Ra 223 dichloride
Succinylcholine